Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach.

IF 30.9 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Lancet Gastroenterology & Hepatology Pub Date : 2021-07-01 Epub Date: 2021-05-04 DOI:10.1016/S2468-1253(21)00020-0
Giovanni Targher, Herbert Tilg, Christopher D Byrne
{"title":"Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach.","authors":"Giovanni Targher,&nbsp;Herbert Tilg,&nbsp;Christopher D Byrne","doi":"10.1016/S2468-1253(21)00020-0","DOIUrl":null,"url":null,"abstract":"<p><p>Non-alcoholic fatty liver disease (NAFLD) is a public health problem worldwide. This narrative Review provides an overview of the current literature to support the notion that NAFLD is a multisystem disease. Convincing evidence shows a strong association between NAFLD and the risk of developing multiple extrahepatic complications such as type 2 diabetes, cardiovascular disease (ie, the predominant cause of mortality in people with NAFLD), chronic kidney disease, and some types of extrahepatic malignancies. The magnitude of this risk parallels the severity of NAFLD (especially the stage of liver fibrosis). There are probably multiple underlying mechanisms by which NAFLD might increase the risk of cardiovascular disease, type 2 diabetes, and extrahepatic complications. Addressing the growing burden of NAFLD will require setting up a multidisciplinary working group and framework to progress and embrace novel collaborative ways of working to deliver holistic, person-centred care and management of people with NAFLD.</p>","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":null,"pages":null},"PeriodicalIF":30.9000,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"160","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lancet Gastroenterology & Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/S2468-1253(21)00020-0","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/5/4 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 160

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a public health problem worldwide. This narrative Review provides an overview of the current literature to support the notion that NAFLD is a multisystem disease. Convincing evidence shows a strong association between NAFLD and the risk of developing multiple extrahepatic complications such as type 2 diabetes, cardiovascular disease (ie, the predominant cause of mortality in people with NAFLD), chronic kidney disease, and some types of extrahepatic malignancies. The magnitude of this risk parallels the severity of NAFLD (especially the stage of liver fibrosis). There are probably multiple underlying mechanisms by which NAFLD might increase the risk of cardiovascular disease, type 2 diabetes, and extrahepatic complications. Addressing the growing burden of NAFLD will require setting up a multidisciplinary working group and framework to progress and embrace novel collaborative ways of working to deliver holistic, person-centred care and management of people with NAFLD.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
非酒精性脂肪肝:一种需要多学科和整体方法的多系统疾病。
非酒精性脂肪性肝病(NAFLD)是一个世界性的公共卫生问题。这篇叙述性综述提供了当前文献的概述,以支持NAFLD是一种多系统疾病的观点。令人信服的证据表明,NAFLD与发生多种肝外并发症(如2型糖尿病、心血管疾病(即NAFLD患者死亡的主要原因)、慢性肾脏疾病和某些类型的肝外恶性肿瘤)的风险之间存在密切关联。这种风险的程度与NAFLD的严重程度相当(尤其是肝纤维化阶段)。NAFLD可能会增加心血管疾病、2型糖尿病和肝外并发症的风险,可能有多种潜在机制。解决NAFLD日益增加的负担需要建立一个多学科工作组和框架,以推进并采用新颖的协作方式,为NAFLD患者提供全面的、以人为本的护理和管理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
50.30
自引率
1.10%
发文量
0
期刊介绍: The Lancet Gastroenterology & Hepatology is an authoritative forum for key opinion leaders across medicine, government, and health systems to influence clinical practice, explore global policy, and inform constructive, positive change worldwide. The Lancet Gastroenterology & Hepatology publishes papers that reflect the rich variety of ongoing clinical research in these fields, especially in the areas of inflammatory bowel diseases, NAFLD and NASH, functional gastrointestinal disorders, digestive cancers, and viral hepatitis.
期刊最新文献
Infliximab rescue therapy in acute severe ulcerative colitis: more does not equal better. Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial. Best buy interventions to address the burden of steatotic liver disease. Global prevalence and characteristics of infections and clinical outcomes in hospitalised patients with cirrhosis: a prospective cohort study for the CLEARED Consortium. Regional disparities of infections in cirrhosis: a call for action.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1